A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

NCT ID: NCT01611363

Last Updated: 2017-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 44 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-10-27
• Study Completion Date: 2012-02-03

Brief Summary

In this study the effect of ipragliflozin on glucose homeostasis in healthy subjects and T2DM subjects, and the effect of exposure of ipragliflozin on urinary glucose excretion and plasma glucose in T2DM subjects will be investigated.

Detailed Description

This study will consist of 2 parts. In Part A the effect of ipragliflozin on the glucose homeostasis will be investigated and in Part B we will investigate the effect of exposure of ipragliflozin on UGE and plasma glucose levels.

Part A

This part will be a randomized, double-blind, placebo-controlled, 2-

period, 2 treatment crossover design in healthy subjects and in T2DM

subjects who are drug naïve or washed out for metformin prior to

admission to the clinical site.

Part B

This part will be an open-label, randomized, 2-period, 2 treatment

crossover design in T2DM subjects stratified by baseline HbA1c

levels (6.0-6.9%, 7.0-7.9%, 8.0-8.9% or 9.0-9.9%).

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: QUADRUPLE

Study Groups

Part A

Ipragliflozin (low dose) \& Placebo

Group Type: EXPERIMENTAL

ASP1941

Intervention Type: DRUG

Oral

Placebo

Intervention Type: DRUG

Oral

Part B

Ipragliflozin (high dose)

Group Type: EXPERIMENTAL

ASP1941

Intervention Type: DRUG

Oral

Interventions

ASP1941

Oral

Intervention Type: DRUG

Placebo

Oral

Intervention Type: DRUG

Other Intervention Names

Ipragliflozin

Eligibility Criteria

Inclusion Criteria

Inclusion Part A: Healthy subjects

• Subject is healthy without diabetes mellitus
• Subject has a fasted plasma glucose (FPG) of less than 5.6 mmol/l at screening
• Subject has a Body Mass Index (BMI) more than or equal to 18.5 and less than 28.0 kg/m2
• Subject's serum creatinine is within the normal range

Inclusion Part A: T2DM subjects

• Subject has been diagnosed with T2DM for at least 6 months
• Subject's body mass index (BMI) is equal to or more than 20.0 and less than 35.0 kg/m2 at screening
• Subject has a HbA1c level above 7.0% and less than 9.0% at screening
• Subject has a (FPG) of less than 10.0 mmol/l
• Subject is treatment naïve to glucose-lowering medication or uses metformin that will be washed out at least 3 weeks prior to the first dosing at Day 1
• Subject's serum creatinine is within the normal range

Inclusion Part B: T2DM subjects

• Subject has a body mass index (BMI) of more than or equal to 20.0 and less than 35.0 kg/m2 at screening.
• Subject has been diagnosed with T2DM for at least 6 months
• Subject has HbA1c level of equal to or more than 6.0% and less than 10% at screening
• Subject has a FPG of less than 10.0 mmol/l
• Subject is drug naïve or on a stable glucose lowering therapy (metformin, TZD, DPP-4 inhibitor or SUD therapy

Exclusion Criteria

Exclusion Part A: Healthy subjects

• Any of the liver function tests above the upper limit of normal
• A QTc interval of >430 ms (males) and >450 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)
• Abnormal pulse and/or blood pressure measurements at screening as follows: Pulse <40 or >90 bpm; mean systolic blood pressure >140 mmHg; mean diastolic blood pressure >90 mmHg
• eGFR (based on Modification of Diet in Renal Disease (MDRD) method) less than 60 ml/min/1.73m2 on Day -2

Exclusion Part A & Part B: T2DM subjects

• Subject has type 1 diabetes mellitus
• A QTc interval of >450 ms (males) and >470 ms (females), a history of unexplained syncope, cardiac arrest, unexplained significant cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS)
• Subject is on an insulin therapy or has received insulin within 3 months prior to screening, with the exception of acute use of <7 days prior to screening
• Subject has a urinary microalbumin/creatinine ratio above or equal to 300 mg/g at screening
• Subject has an ALT and/or AST higher than 3 times the upper limit of normal or has a total bilirubin more than 2 times the upper limit of normal at screening
• Subject has a symptomatic urinary tract infection or symptomatic genito-urinary infection at screening
• Subject has persistent, uncontrolled severe hypertension as indicated by a mean systolic blood pressure > 160 mmHg or a mean diastolic blood pressure of > 100 mmHg
• Subject has significant cardiovascular disease
• eGFR (based on MDRD method) less than 60 ml/min/1.73m2 on Day -2

• Minimum Eligible Age: 35 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Astellas Pharma Europe B.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Study Manager

Role: STUDY_DIRECTOR

Astellas Pharma Europe B.V.

Locations

Neuss, , Germany

Countries

Germany

Related Links

https://www.astellasclinicalstudyresults.com/study.aspx?ID=4

Link to results on Astellas Clinical Study Results website

Other Identifiers

2010-024070-19

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

1941-CL-0050

Identifier Type: -

Identifier Source: org_study_id